Trial
NCT01479010
Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Virginia Commonwealth University
Collaborators
—
Condition
Pulmonary Hypertension
Intervention
Anakinra 100 mg subcutaneously daily
Why stopped
recruitment issues, critical investigators left institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-13